Amir Fathi, MD, discusses one of the biggest nonfinancial barriers to bispecific therapies: the expertise required to safely administer and manage them.

A new study by Indiana University School of Medicine researchers has revealed a breakthrough in the fight against acute myeloid leukemia, one of the most aggressive and fatal blood cancers in adults.

A large new study has confirmed the clinical relevance of a pharmacogenomic score that could help tailor leukaemia treatment ...

MUSC researchers at the Hollings Cancer center are making strides in new developments for leukemia treatment.Sophie Paczesny, ...

The patients receiving AHSCT had 5-year LFS of 46.3% and OS of 53.3%, which were better outcomes than those of the MRC UKALL XII/ECOG E2993 trial conducted from 2006 to 2010.